Definium Therapeutics: JPMorgan initiates coverage with overweight rating; target price $84
DFTX•JPMorgan initiated coverage of Definium Therapeutics with an overweight rating and an $84 target price.
Related News
AI-related companies to drive most third-quarter US earnings gains
SPY•
Brazil election to reshape trade with US, with tariffs and minerals at stake
EWZ•
Lear Corporation: Barclays cuts target price to $145 from $155
LEA•
Sea CCO, GC Wang Yanjun disposes 2,000 common shares worth $188,387
SE•
Firefly Aerospace receives Barclays equal-weight rating and $34 target price
FLY•